Q-omics provides the consensus-scored ZNF367 profile across patient tissues and cancer cell-line models. ZNF367 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZNF367 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, ZNF367 RNA expression shows 22,502 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, HNSC, and LSCC as cancer lineages where ZNF367 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF367 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF367 survival associations across molecular data types. ZNF367 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF367 RNA expression–survival associations across cancer types. High ZNF367 expression shows unfavorable associations in MESO, ACC, KIRP and LGG, but favorable associations in KIRC and SKCM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZNF367 RNA expression.
This table summarizes ZNF367 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF367. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF367 shows lower tumor expression in KICH and higher tumor expression in HNSC, COAD, LUSC, STAD and UCEC. The HNSC box plot shows higher ZNF367 RNA expression in tumor versus normal tissue (log2 FC = +1.311, t-test p < 0.001).
This table shows molecular features associated with ZNF367 in patient tissues and cancer cell lines. In patient samples, ZNF367 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF367 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
